Tracer library / [68Ga]C803-GIP

[68Ga]C803-GIP

Also written as [Ga-68]Ga-C803-GIP

Radionuclide: Ga-68 t½ 67.71 min
Modality: PET
Production route: —
Stage: Reported once
Syntheses indexed: 1

Neuroendocrine neoplasms Receptor expression phenotyping

What it is

Compound class: DOTA-conjugated GIP/exendin-4 hybrid peptide (GIPR-targeting peptide)
Target / mechanism: GIPR (glucose-dependent insulinotropic polypeptide receptor) PMID 36678558
Clinical application: PET imaging of GIPR expression, potential in neuroendocrine neoplasms PMID 36678558
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
—	—	SPE	61.1 ± 2.9% not corrected	94.5 ± 0.3%	C803-GIP Sanofi	36678558 2022 Pharmaceuticals (Basel)

Precursor

Common precursor: —
Suppliers seen in the literature: —
Cited suppliers in indexed syntheses: Sanofi
Typical final purification: —

Need this precursor?We can point you to suppliers for [68Ga]C803-GIP, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 36678558. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. | Stage 30 (2026-09-18): Modality was 'Therapy' -- a bucket value given to every agent found by the therapy-oriented bulk search (stages 21-22), not a source statement. Corrected to PET: Ga-68 is a positron emitter used only for PET imaging. Linked articles: PMID 36678558.